Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Fujitsu begins two-year medical AI research project

Partners with Kyoto University on R&D-focused work

Artificial intelligence AI pharma healthcare

Japanese IT company Fujitsu is collaborating with Kyoto University on a two-year project to investigate the use of artificial intelligence in medicine.

The partners are focused on AI’s possibilities in accelerating the research and development of next-generation medicine, such as new approaches to diagnostics and drug discovery.

The work will be run from the newly-established Department of Medical Intelligent Systems within Kyoto University.

The medical information put to use will include cancer patient data and patient data from electronic medical records collected by Kyoto University Hospital.

The firms say that existing AI technology has yet to adequately integrated the huge volumes of data from sources such as electronic medical records, medical journals and genomic data.

“To put this data to use, it has become essential to develop AI for medicine through the close collaboration of researchers with a high degree of knowledge of the medical field with AI researchers and engineers,” Fujitsu said in a statement.

Meanwhile, last year saw an uptick in life sciences interest in applying AI to drug research, with the likes of Scotland’s Exscientia scoring deals with GSK, Evotec and Sanofi, and Lundbeck signing up with IBM Watson Health.

1st February 2018

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics